Hua, Rui
Kong, Fei
Li, Guangming
Wen, Xiaofeng
Zhang, Yuexin
Yang, Xingxiang
Meng, Chenxin
Xie, Wen
Jiang, Yongfang
Wang, Xiaozhong
Han, Xueji
Huang, Yan
Mao, Qing
Wang, Jiefei
Guan, Yujuan
Chen, Jiayu
Ma, Yingjie
Xiong, Qingfang
Ma, Hong
Yan, Xuebing
Rao, Huiying
Zhao, Yingren
Sun, Tong
Zhu, Liying
Mao, Xiaorong
Lian, Jianqi
Deng, Guojiong
Xin, Yongning
Wang, Yifei
Ye, Yinong
Xu, Bin
Gao, Hainv
Tan, Youwen
Li, Dongliang
Yang, Dongliang
Su, Minghua
Zhang, Xiaomeng
Min, Jie
Shi, Xinsheng
Wei, Lai
Niu, Junqi
Clinical trials referenced in this document:
Documents that mention this clinical trial
Alfosbuvir plus Daclatasvir for Treatment of Chronic Hepatitis C Virus Infection in China
https://doi.org/10.1007/s40121-023-00872-4
Funding for this research was provided by:
National Science and Technology Major Project of China for Significant New Drugs Creation (2019ZX09302053, 2020ZX09101027)
Article History
Received: 17 July 2023
Accepted: 5 September 2023
First Online: 19 October 2023
Declarations
:
: Xiaomeng Zhang, Jie Min, and Xinsheng Shi are employees of Nanjing Sanhome Pharmaceutical Co., Ltd. The other authors have no conflict of interest to declare. Rui Hua, Fei Kong, Guangming Li, Xiaofeng Wen, Yuexin Zhang, Xingxiang Yang, Chenxin Meng, Wen Xie, Yongfang Jiang, Xiaozhong Wang, Xueji Han, Yan Huang, Qing Mao, Jiefei Wang, Yujuan Guan, Jiayu Chen, Yingjie Ma, Qingfang Xion, Hong Ma, Xuebing Yan, Huiying Rao, Yingren Zhao, Tong Sun, Liying Zhu, Xiaorong Mao, Jianqi Lian, Guojiong Deng, Yongning Xin, Yifei Wang, Yinong Ye, Bin Xu, Hainv Gao, Youwen Tan, Dongliang Li, Dongliang Yang, Minghua Su, Junqi Niu, and Lai Wei have nothing to disclose.
: This study was carried out by 35 centers, including the First Hospital of Jilin University. Relevant clinical trial protocols, informed consent, case report forms, and researcher manuals were reviewed by the Ethics Committee of the First Hospital of Jilin University for the first time on 26 December 2018, and the opinion was “agree” with ethics approval no. 18Y248-001.
: Written informed consent was obtained from all patients prior to enrollment and initiation of any study procedures. The study was approved by an independent ethics committee at each participating site, and we obtained ethics committee approval from all 35 research centers prior to the study commencing. It is carried out in accordance with the principles of the Declaration of Helsinki, China’s legal and regulatory requirements, and good clinical practice. The trial was conducted in mainland China, and no IRB approval was sought.